Liquidia (LQDA) Is Down 5.5% After YUTREPIA’s Launch Outpaces Expectations Amid Ongoing Patent Fight

Simply Wall St.00:07

In early 2026, Laughing Water Capital’s Q1 investor letter highlighted that Liquidia’s inhaled treprostinil therapy YUTREPIA has been launching with sales that continue to exceed expectations, while ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2630335171?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-04-27 00:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630335171","market":"sg","top_or_hot":-1,"title":"Liquidia (LQDA) Is Down 5.5% After YUTREPIA’s Launch Outpaces Expectations Amid Ongoing Patent Fight","media":"Simply Wall St.","content":"<div>\n<p>In early 2026, Laughing Water Capital’s Q1 investor letter highlighted that Liquidia’s inhaled treprostinil therapy YUTREPIA has been launching with sales that continue to exceed expectations, while ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/liquidia-lqda-is-down-55-after-yutrepias-launch-outpaces-exp\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Liquidia (LQDA) Is Down 5.5% After YUTREPIA’s Launch Outpaces Expectations Amid Ongoing Patent Fight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLiquidia (LQDA) Is Down 5.5% After YUTREPIA’s Launch Outpaces Expectations Amid Ongoing Patent Fight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-27 00:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/liquidia-lqda-is-down-55-after-yutrepias-launch-outpaces-exp><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In early 2026, Laughing Water Capital’s Q1 investor letter highlighted that Liquidia’s inhaled treprostinil therapy YUTREPIA has been launching with sales that continue to exceed expectations, while ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/liquidia-lqda-is-down-55-after-yutrepias-launch-outpaces-exp\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/liquidia-lqda-is-down-55-after-yutrepias-launch-outpaces-exp","article_id":"2630335171","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/liquidia-lqda-is-down-55-after-yutrepias-launch-outpaces-exp","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2630335171","pubTimestamp":1777219652,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In early 2026, Laughing Water Capital’s Q1 investor letter highlighted that Liquidia’s inhaled treprostinil therapy YUTREPIA has been launching with sales that continue to exceed expectations, while patent litigation with United Therapeutics over its use in PH-ILD remains unresolved.\nThe letter underscored that legal experts now see a favorable outcome as increasingly likely and suggested that strong YUTREPIA adoption, combined with a positive ruling, could support an annualized revenue run...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LQDA":"Liquidia Technologies Inc"},"translate_title":"在持续的专利斗争中，YUTREPIA的推出超出预期，Liquidia(LQDA)股价下跌5.5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LQDA":1.5},"content_text":"In early 2026, Laughing Water Capital’s Q1 investor letter highlighted that Liquidia’s inhaled treprostinil therapy YUTREPIA has been launching with sales that continue to exceed expectations, while patent litigation with United Therapeutics over its use in PH-ILD remains unresolved. The letter underscored that legal experts now see a favorable outcome as increasingly likely and suggested that strong YUTREPIA adoption, combined with a positive ruling, could support an annualized revenue run rate above US$1.20 billion by year-end if current trends persist. We’ll now examine how this optimism around YUTREPIA’s above-expectation launch may reshape Liquidia’s existing investment narrative and risk-reward profile. The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AdvertisementLiquidia Investment Narrative RecapTo own Liquidia today, you need to believe that YUTREPIA can grow into a leading inhaled treprostinil franchise while the unresolved United Therapeutics litigation is ultimately contained. Laughing Water Capital’s letter reinforces YUTREPIA’s strong early launch as the key near term catalyst, but also highlights that the court outcome on PH ILD use remains the single biggest swing factor for the business and for how sustainable any current sales strength may prove. The most relevant recent announcement here is Liquidia’s Q4 2025 result, where revenue reached US$92.02 million and the company generated quarterly net income of US$14.56 million. Those numbers show how quickly YUTREPIA has started to contribute financially and provide context for the investor letter’s confidence that, if legal outcomes cooperate, the current sales trajectory could materially change how investors frame both upside potential and downside risk. Yet investors should also understand how a less favorable patent ruling could affect YUTREPIA’s long term revenue, margins and even its continued availability… Read the full narrative on Liquidia (it's free!)Liquidia's narrative projects $717.7 million revenue and $299.9 million earnings by 2029. This requires 118.1% yearly revenue growth and a $424.0 million earnings increase from -$124.1 million today.Uncover how Liquidia's forecasts yield a $44.00 fair value, a 18% upside to its current price.Exploring Other PerspectivesLQDA 1-Year Stock Price Chart Before this news, the most optimistic analysts were already modeling revenue above US$1.0 billion and earnings near US$603.6 million by 2028, which is far more aggressive than consensus and could either be reinforced or challenged depending on how the YUTREPIA litigation and commercialization story now evolves.Explore 5 other fair value estimates on Liquidia - why the stock might be worth over 6x more than the current price!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Liquidia research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free Liquidia research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Liquidia's overall financial health at a glance.Ready For A Different Approach?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2630335171","isCrawlerRequest":true}